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Data sharing and reanalysis of randomized controlled trials in 
leading biomedical journals with a full data sharing policy: survey 
of studies published in The BMJ and PLOS Medicine
Florian Naudet,1 Charlotte Sakarovitch,2 Perrine Janiaud,1 Ioana Cristea,1,3 Daniele Fanelli,1,4 
David Moher,1,5 John P A Ioannidis1,6
ABSTRACT
OBJECTIVES
To explore the effectiveness of data sharing by 
randomized controlled trials (RCTs) in journals with 
a full data sharing policy and to describe potential 
difficulties encountered in the process of performing 
reanalyses of the primary outcomes.
DESIGN
Survey of published RCTs.
SETTING
PubMed/Medline.
ELIGIBILITY CRITERIA
RCTs that had been submitted and published by The 
BMJ and PLOS Medicine subsequent to the adoption 
of data sharing policies by these journals.
MAIN OUTCOME MEASURE
The primary outcome was data availability, defined 
as the eventual receipt of complete data with clear 
labelling. Primary outcomes were reanalyzed to assess 
to what extent studies were reproduced. Difficulties 
encountered were described.
RESULTS
37 RCTs (21 from The BMJ and 16 from PLOS Medicine) 
published between 2013 and 2016 met the eligibility 
criteria. 17/37 (46%, 95% confidence interval 30% to 
62%) satisfied the definition of data availability and 
14 of the 17 (82%, 59% to 94%) were fully reproduced 
on all their primary outcomes. Of the remaining RCTs, 
errors were identified in two but reached similar 
conclusions and one paper did not provide enough 
information in the Methods section to reproduce the 
analyses. Difficulties identified included problems 
in contacting corresponding authors and lack of 
resources on their behalf in preparing the datasets. 
In addition, there was a range of different data 
sharing practices across study groups.
CONCLUSIONS
Data availability was not optimal in two journals 
with a strong policy for data sharing. When 
investigators shared data, most reanalyses largely 
reproduced the original results. Data sharing 
practices need to become more widespread and 
streamlined to allow meaningful reanalyses and 
reuse of data.
TRIAL REGISTRATION
Open Science Framework osf.io/c4zke.
Introduction
Patients, medical practitioners, and health policy 
analysts are more confident when the results and 
conclusions of scientific studies can be verified. For 
a long time, however, verifying the results of clinical 
trials was not possible, because of the unavailability 
of the data on which the conclusions were based. 
Data sharing practices are expected to overcome this 
problem and to allow for optimal use of data collected 
in trials: the value of medical research that can inform 
clinical practice increases with greater transparency 
and the opportunity for external researchers to 
reanalyze, synthesize, or build on previous data.
In 2016 the International Committee of Medical 
Journal Editors (ICMJE) published an editorial1 stating 
that “it is an ethical obligation to responsibly share 
data generated by interventional clinical trials because 
participants have put themselves at risk.” The ICMJE 
proposed to require that deidentified individual patient 
data (IPD) are made publicly available no later than 
six months after publication of the trial results. This 
proposal triggered debate.2-7 In June 2017, the ICMJE 
stepped back from its proposal. The new requirements 
do not mandate data sharing but only a data sharing 
plan to be included in each paper (and prespecified in 
study registration).8
Because of this trend toward a new norm where 
data sharing for randomized controlled trials (RCTs) 
becomes a standard, it seems important to assess 
how accessible the data are in journals with existing 
data sharing policies. Two leading general medical 
journals, The BMJ9 10 and PLOS Medicine,11 already 
have a policy expressly requiring data sharing as a 
condition for publication of clinical trials: data sharing 
became a requirement after January 2013 for RCTs on 
drugs and devices9 and July 2015 for all therapeutics10 
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WhAT IS AlReAdy knoWn on ThIS TopIC
The International Committee of Medical Journal Editors requires that a data 
sharing plan be included in each paper (and prespecified in study registration)
Two leading general medical journals, The BMJ and PLOS Medicine, already have 
a stronger policy, expressly requiring data sharing as a condition for publication 
of randomized controlled trials (RCTs)
Only a small number of reanalyses of RCTs has been published to date; of these, 
a minority was conducted by entirely independent authors
WhAT ThIS STudy AddS
Data availability was not optimal in two journals with a strong policy for data 
sharing, but the 46% data sharing rate observed was higher than elsewhere in 
the biomedical literature
When reanalyses are possible, these mostly yield similar results to the original 
analysis; however, these reanalyses used data at a mature analytical stage
Problems in contacting corresponding authors, lack of resources in preparing 
the datasets, and important heterogeneity in data sharing practices are barriers 
to overcome
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at The BMJ, and after March 2014 for all types of 
interventions at PLOS Medicine.
We explored the effectiveness of RCT data sharing in 
both journals in terms of data availability, feasibility, 
and accuracy of reanalyses and describe potential 
difficulties encountered in the process of performing 
reanalyses of the primary outcomes. We focused on 
RCTs because they are considered to represent high 
quality evidence and because availability of the data 
is crucial in the evaluation of health interventions. 
RCTs represent the most firmly codified methodology, 
which also allows data to be most easily analyzed. 
Moreover, RCTs have been the focus of transparency 
and data sharing initiatives,12 owing to the importance 
of primary data availability in the evaluation of 
therapeutics (eg, for IPD meta-analyses).
Methods
The methods were specified in advance. They were 
documented in a protocol submitted for review on 12 
November 2016 and subsequently registered with the 
Open Science Framework on 15 November 2016 (https://
osf.io/u6hcv/register/565fb3678c5e4a66b5582f67).
Eligibility criteria
We surveyed publications of RCTs, including cluster 
trials and crossover studies, non-inferiority designs, 
and superiority designs, that had been submitted and 
published by The BMJ and PLOS Medicine subsequent to 
the adoption of data sharing policies by these journals.
Search strategy and study selection
We identified eligible studies from PubMed/Medline. For 
The BMJ we used the search strategy: “BMJ”[jour] AND 
(“2013/01/01”[PDAT]: “2017/01/01”[PDAT]) AND 
Randomized Controlled Trial[ptyp]. For PLOS Medicine 
we used: “PLoS Med”[jour]) AND (“2014/03/01”[PDAT]: 
“2017/01/01”[PDAT]) AND Randomized Controlled 
Trial[ptyp].
Two reviewers (FN and PJ) performed the eligibility 
assessment independently. Disagreements were 
resolved by consensus or in consultation with a third 
reviewer (JPAI or DM). More specifically, the eligibility 
assessment was based on the date of submission, not 
on the date of publication. When these dates were not 
available we contacted the journal editors for them.
Data extraction and datasets retrieval
A data extraction sheet was developed. For each 
included study we extracted information on study 
characteristics (country of corresponding author, 
design, sample size, medical specialty and disease, 
and funding), type of intervention (drug, device, other), 
and procedure to gather the data. Two authors (FN and 
PJ) independently extracted the data from the included 
studies. Disagreements were resolved by consensus 
or in consultation with a third reviewer (JPAI). One 
reviewer (FN) was in charge of retrieving the IPD for all 
included studies by following the instructions found 
in the data sharing statement of the included studies. 
More specifically, when data were available on request, 
we sent a standardized email (https://osf.io/h9cas/). 
Initial emails were sent from a professional email 
address (fnaudet@stanford.edu), and three additional 
reminders were sent to each author two or three weeks 
apart, in case of non-response.
Data availability
Our primary outcome was data availability, defined as 
the eventual receipt of data presented with sufficient 
information to reproduce the analysis of the primary 
outcomes of the included RCTs (ie, complete data with 
clear labelling). Additional information was collected 
on type of data sharing (request by email, request 
using a specific website, request using a specific 
register, available on a public register, other), time for 
collecting the data (in days, time between first attempt 
to success of getting a database), deidentification 
of data (concerning name, birthdate, and address), 
type of data shared (from case report forms to directly 
analyzable datasets),13 sharing of analysis code, and 
reasons for non-availability in case data were not 
shared.
Reproducibility
When data were available, a single researcher (FN) 
carried out a reanalysis of the trial. For each study, 
analyses were repeated exactly as described in the 
published report of the study. Whenever insufficient 
details about the analysis was provided in the 
study report, we sought clarifications from the trial 
investigators. We considered only analyses concerning 
the primary outcome (or outcomes, if multiple primary 
outcomes existed) of each trial. Any discrepancy 
between results obtained in the reanalysis and 
those reported in the publication was examined in 
consultation with a statistician (CS). This examination 
aimed to determine if, based on both quantitative 
(effect size, P values) and qualitative (clinical 
judgment) consideration, the discrepant results of the 
reanalysis entailed a different conclusion from the one 
reported in the original publication. Any disagreement 
or uncertainty over such conclusions was resolved 
by consulting a third coauthor with expertise in both 
clinical medicine and statistical methodology (JPAI). 
If, after this assessment process, it was determined 
that the results (and eventually conclusions) were 
still not reproduced, CS independently reanalyzed 
the data to confirm such a conclusion. Once the “not 
reproduced” status of a publication was confirmed, 
FN contacted the authors of the study to discuss the 
source of the discrepancy. After this assessment 
procedure, we classified studies into four categories: 
fully reproduced, not fully reproduced but same 
conclusion, not reproduced and different conclusion, 
and not reproduced (or partially reproduced) because 
of missing information.
Difficulties in getting and using data or code and 
performing reanalyses
We noted whether the sharing of data or analytical 
code, or both, required clarifications for which 
RESEARCH
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additional queries had to be presented to the authors 
to obtain the relevant information, clarify labels or 
use, or both, and reproduce the original analysis of 
the primary outcomes. A catalogue of these queries 
was created and we grouped similar clarifications for 
descriptive purposes to generate a list of some common 
challenges and to help tackle these challenges pre-
emptively in future published trials.
Statistical analyses
We computed percentages of data sharing or 
reproducibility with 95% confidence intervals based 
on binomial approximation or on Wilson score method 
without continuity correction if necessary.14 For the 
purposes of registration, we hypothesized that if these 
data sharing policies were effective they would lead to 
more than 80% of studies sharing their data (ie, the 
lower boundary of the confidence interval had to be 
more than 80%). High rates of data sharing resulting 
from full data sharing policies should be expected. On 
the basis of experience of explicit data sharing policies 
in Psychological Science,15 however, we knew that a 
rate of 100% was not realistic and judged that an 80% 
rate could be a desirable outcome.
When data were available, one researcher (FN) 
performed reanalyses using the open source statistical 
software R (R Development Core Team), and the senior 
statistician (CS) used SAS (SAS Institute). In addition, 
when authors shared their codes (in R, SAS, STATA 
(StataCorp 2017) or other), these were checked and 
used. Estimates of effect sizes, 95% confidence intervals, 
and P values were obtained for each reanalysis.
Changes from the initial protocol
Initially we planned to include all studies published 
after the data sharing policies were in place. 
Nevertheless, some authors who we contacted 
suggested that their studies were not eligible because 
the papers were submitted to the journal before 
the policy. We contacted editors who confirmed 
that policies applied for papers submitted (and not 
published) after the policy was adopted. In accordance, 
and to avoid any underestimation of data sharing rates, 
we changed our selection criteria to “studies submitted 
and published after the policy was adopted.” For a few 
additional studies submitted before the policy, data 
were collected and reanalyzed but only described in 
the web appendix.
For the reanalysis we initially planned to consider 
non-reproducibility as a disagreement between 
reanalyzed results and results reported in the original 
publication by more than 2% in the point estimate 
or 95% confidence interval. After reanalysis of a 
couple of studies we believed that such a definition 
was sometimes meaningless. Interpreting a RCT 
involves clinical expertise and cannot be reduced to 
solely quantitative factors. Accordingly, we changed 
our definition and provided a detailed description 
of reanalyses and published results, mentioning 
the nature of effect size and the type of outcome 
considered.
Patient involvement
We had no established contacts with specific patient 
groups who might be involved in this project. No 
patients were involved in setting the research question 
or the outcome measures, nor were they involved in 
the design and implementation of the study. There 
are no plans to involve patients in the dissemination 
of results, nor will we disseminate results directly to 
patients.
Results
Characteristics of included studies
Figure 1 shows the study selection process. The 
searches done on 12 November 2016 resulted in 159 
citations. Of these, 134 full texts were considered for 
eligibility. Thirty seven RCTs (21 from The BMJ and 
16 from PLOS Medicine) published between 2013 
and 2016 met our eligibility criteria. Table 1 presents 
Records identied through database searching (n=159):
  The BMJ (n=120)
  PLOS Medicine (n=39)
Records excluded based on title and abstract (n=25):
  The BMJ (non-randomised controlled trials) (n=20)
  PLOS Medicine (non-randomised controlled trials) (n=5)
Data not available (n=20):
   The BMJ (n=13)
   PLOS Medicine (n=7)
Full text meeting inclusion criteria published aer the policy
 (n=62):
   The BMJ (n=32)
   PLOS Medicine (n=30)
Full text meeting inclusion criteria submitted aer the policy
 (n=37):
   The BMJ (n=21)
   PLOS Medicine (n=16)
Record excluded because submitted before the policy
 (n=25):
   The BMJ (n=11)
   PLOS Medicine (n=14)
Full text considered for eligibility (n=134):
  The BMJ (n=100)
  PLOS Medicine (n=34)
Data available (n=17):
  The BMJ (n=8)
  PLOS Medicine (n=9)
Analyses fully reproduced (n=14):
  The BMJ (n=7)
  PLOS Medicine (n=7)
Analyses not reproduced because of missing information (n=1):
  PLOS Medicine (n=1)
Analyses not fully reproduced but same conclusion (n=2):
  The BMJ (n=1)
  PLOS Medicine (n=1)
Records excluded based on full text (n=72):
  The BMJ (n=68):
    No policy (n=55)
    Reanalyses (n=2)
    Secondary analyses (n=11)
  PLOS Medicine (n=4):
    Secondary analyses (n=4)
Fig 1 | Study flow diagram
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the characteristics of these studies. These RCTs had a 
median sample size of 432 participants (interquartile 
range 213-1070), had no industry funding in 26 cases 
(70%), and were led by teams from Europe in 25 cases 
(67%). Twenty RCTs (54%) evaluated pharmacological 
interventions, 9 (24%) complex interventions (eg, 
psychotherapeutic program), and 8 (22%) devices.
Data availability
We were able to access data for 19 out of 37 studies 
(51%). Among these 19 studies, the median number 
of days for collecting the data was 4 (range 0-191). 
Two of these studies, however, did not provide 
sufficient information within the dataset to enable 
direct reanalysis (eg, had unclear labels). Therefore 
17 studies satisfied our definition of data availability. 
The rate of data availability was 46% (95% confidence 
interval 30% to 62%).
Data were in principle available for two additional 
studies not included in the previous count and both 
authored by the same research team. However, the 
authors asked us to cover the financial costs of preparing 
the data for sharing (£607; $857; €694). Since other 
teams shared the data for free, we considered that it 
would not have been fair to pay some and not others 
for similar work in the context of our project and so we 
classified these two studies as not sharing data. For a 
third study, the authors were in correspondence with 
us and discussing conditions for sharing data, but we 
did not receive that data by the time our data collection 
process was determined to be over (seven months). If 
these three studies were included, the proportion of 
data sharing would be 54% (95% confidence interval 
38% to 70%).
For the remaining 15 studies classified as not sharing 
data, reasons for non-availability were: no answer to 
Table 1 | Characteristics of included studies. Values are numbers (percentages) unless stated otherwise
Characteristics All (37 studies) The BMJ (21 studies) PLOS Medicine (16 studies)
Geographical area of lead country:
 Europe 25 (67) 17 (80) 8 (50)
 Australia and New Zealand 4 (11) 1 (5) 3 (19)
 Northern America 3 (8) 1 (5) 2 (12.5)
 Africa 3 (8) 1 (5) 2 (12.5)
 East Asia 1 (3) 0 (0) 1 (6)
 Middle East 1 (3) 1 (5) 0 (0)
Type of intervention:
 Drug 20 (54) 13 (62) 7 (44)
 Device 8 (22) 8 (38) 0 (0)
 Complex intervention 9 (24) 0 (0) 9 (56)
Medical specialty:
 Infectious disease 12 (33) 4 (19) 8 (50)
 Rheumatology 5 (14) 5 (24) 0 (0)
 Endocrinology/nutrition 4 (11) 1 (5) 3 (19)
 Paediatrics 3 (8) 2 (9) 1 (6)
 Mental health/addiction 2 (5) 1 (5) 1 (6)
 Obstetrics 2 (5) 1 (5) 1 (6)
 Emergency medicine 2 (5) 2 (9) 0 (0)
 Geriatrics 2 (5) 0 (0) 2 (13)
 Other 5 (14) 5 (24) 0 (0)
Designs:
 Superiority (head to head) 18 (49) 15 (71) 3 (19)
 Superiority (factorial) 1 (3) 1 (5) 0 (0)
 Superiority (clusters) 8 (21) 1 (5) 7 (43)
 Non-inferiority+superiority (head to head) 4 (11) 1 (5) 3 (19)
 Non-inferiority (head to head) 6 (16) 3 (14) 3 (19)
Median (interquartile range) sample size 432 (213-1070)* 221 (159-494) 1047 (433-2248)*
Private sponsorship:
 No 26 (70) 15 (71) 11 (69)
 Provided device 1 (3) 1 (5) 0 (0)
 Provided intervention 1 (3) 0 (0) 1 (6)
 Provided drug 5 (13) 1 (5) 4 (25)
 Provided drug and some financial support 2 (5) 2 (9) 0 (0)
 Provided partial financial support 1 (3) 1 (5) 0 (0)
 Provided total financial support 1 (3) 1 (5) 0 (0)
Statement of availability:
 Ask to contact by email 23 (62) 17 (81) 6 (38)
 Explain how to retrieve data (eg, platform) 9 (24) 0 (0) 9 (56)
 State “no additional data available” 2 (5) 2 (9) 0 (0)
 Ask to contact by mail 1 (3) 0 (0) 1 (6)
 Embargo 1 (3) 1 (5) 0 (0)
 No statement 1 (3) 1 (5) 0 (0)
Rounded percentages add up to 100% for each variable.
*Exact sample size was not reported for one cluster trial in PLOS Medicine.
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the different emails (n=7), no answer after an initial 
agreement (n=2), and refusal to share data (n=6). 
Explanations for refusal to share data included lack 
of endorsement of the objectives of our study (n=1), 
personal reasons (eg, sick leave, n=2), restrictions 
owing to an embargo on data sharing (n=1), and no 
specific reason offered (n=2). The existence of possible 
privacy concerns was never put forward as a reason for 
not sharing data.
Among the 19 studies sharing some data (analyzable 
datasets and non-analyzable datasets), 16 (84%) 
datasets were totally deidentified. Birthdates were 
found in three datasets and geographical information 
(country and postcode) in one of these three. Most 
datasets were data ready for analysis (n=17), whereas 
two required some additional processing before the 
analysis could be repeated. In these two cases, such 
processing was difficult to implement (even with the 
code being available) and the authors were contacted 
to share analyzable data. Statistical analysis code was 
available for seven studies (including two that were 
obtained after a second specific request).
Reproducibility
Among the 17 studies16-32 providing sufficient data for 
reanalysis of their primary outcomes, 14 (82%, 95% 
confidence interval 59% to 94%) studies were fully 
reproduced on all their primary outcomes. One of the 
17 studies did not provide enough information in the 
Methods section for the analyses to be reproduced 
(specifically, the methods used for adjustment were 
unclear). We contacted the authors of this study to 
obtain clarifications but received no reply. Of the 
remaining 16 studies, we reanalyzed 47 different 
primary analyses. Two of these studies were considered 
not fully reproduced. For one study, we identified an 
error in the statistical code and for the other we found 
slightly different numerical values for the effect sizes 
measured as well as slight differences in numbers of 
patients included in the analyses (a difference of one 
patient in one of four analyses). Nevertheless, similar 
conclusions were reached in both cases (these two 
studies were categorized as not fully reproduced but 
reaching the same conclusion). Therefore, we found no 
results contradicting the initial publication, neither in 
terms of magnitude of the effect (table 2) nor in terms 
of statistical significance of the finding (fig 2).
We retrieved the data of three additional studies, 
published in The BMJ after its data sharing policy was 
in place (but submitted before the policy). Although 
these studies were ineligible for our main analysis, 
reanalyses were performed and also reached the same 
conclusions as the initial study (see supplementary 
e-Table 1).
Difficulties in getting and using data or code and 
performing reanalyses
Based on our correspondence with authors, we 
identified several difficulties in getting the data. A 
common concern pertained to the costs of the data 
sharing process—for example, the costs of preparing 
the data or translating the database from one language 
to another. Some authors wondered whether their team 
or our team should assume these costs. In addition, 
some of the authors balanced these additional costs 
with their perceived benefits of sharing data for the 
purpose of this study and seemed to rather value data 
sharing for the purpose of a meta-analysis than for 
reanalyses, possibly because of the risk acknowledged 
by one investigator we contacted about “naming and 
shaming” individual studies or investigators.
Getting prepared and preplanning for data sharing 
still seems to be a challenge for many trial groups; 
data sharing proved to be novel for some authors 
who were unsure how to proceed. Indeed, there 
was considerable heterogeneity between different 
procedures to share data: provided in an open 
repository (n=5), downloadable on a secured website 
(n=1) after registration, included as appendix of the 
published paper (n=3), or sent by email (n=10). On 
three occasions, we signed a data sharing request or 
agreement. In these agreements, the sponsor and 
recipient parties specified the terms that bound them 
in the data sharing process (eg, concerning the use of 
data, intellectual property, etc). In addition, typically 
there was no standard in what type of data were shared 
(at what level of cleaning and processing). In one 
case, authors mentioned explicitly that they followed 
standardized guidelines33 to prepare the dataset.
Some analyses were complex and it was sometimes 
challenging to reanalyze data from specific designs or 
when unusual measures were used (eg, relative change 
in percentage). Obtaining more information about the 
analysis by contacting authors was necessary for 6 of 
17 studies to replicate the findings. In one case, specific 
exploration of the code revealed that in a survival 
analysis, authors treated repeated events in the same 
patient (multiple events) as distinct observations. 
This was in disagreement with the methods section 
describing usual survival analysis (taking into 
account only the first event for each patient). However, 
alternative analyses did not contradict the published 
results.
Three databases did not provide sufficient 
information to reproduce the analyses. Missing data 
concerned variables used for adjustment, definition of 
the analysis population, and randomization groups. 
Communication with authors was therefore necessary 
and was fruitful in one of these three cases.
discussion
In two prominent medical journals with a strong data 
sharing policy for randomized controlled trials (RCTs), 
we found that for 46% (95% confidence interval 30% 
to 62%) of published articles the original investigators 
shared their data with sufficient information to enable 
reanalyses. This rate was less than the 80% boundary 
that we prespecified as an acceptable threshold for 
papers submitted under a policy that makes data 
sharing an explicit condition for publication. However, 
despite being lower than might be desirable, a 46% 
data sharing rate is much higher than the average rate 
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of biomedical literature at large, in which data sharing 
is almost non-existent34 (with few exceptions in some 
specific disciplines, such as genetics).35 Moreover, our 
analyses focused on publications that were submitted 
directly after the implementation of new data sharing 
policies, which might be expected to have practical 
and cultural barriers to their full implementation. 
Indeed, our correspondence with the authors helped 
identify several practical difficulties connected to 
data sharing, including difficulties in contacting 
corresponding authors, and lack of time and financial 
resources on their behalf in preparing the datasets for 
us. In addition, we found a wide variety of data sharing 
practices between study groups (ie, regarding the type 
of data that can be shared and the procedures that 
are necessary to follow to get the data). Data sharing 
practices could evolve in the future to deal with these 
barriers to data sharing (table 3).
For all results that we were able to reanalyze, we 
reached similar conclusions (despite occasional slight 
differences in the numerical estimations) to those 
reported in the original publication, and this result that 
at least the available data shared do correspond closely 
to the reported results is reassuring. Of course, there is 
a large amount of diversity on what exactly “raw data” 
mean and they can involve various transformations 
(from the case report forms to coded and analyzable 
data).13 Here, we relied on late stage, coded, and 
cleaned data and therefore the potential for leading 
to a different conclusion was probably small. Data 
processing, coding, cleaning, and recategorization of 
events can have a substantial impact on the results 
in some trials. For example, SmithKline Beecham’s 
Study 329 was a well known study on paroxetine in 
adolescent depression, presenting the drug as safe and 
effective,36 whereas a reanalysis starting from the case 
report forms found a lack of efficacy and some serious 
safety issues.37
Strengths and weaknesses of this study
Some leading general medical journals—New England 
Journal of Medicine, Lancet, JAMA, and JAMA Internal 
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Fig 2 | P values in initial analyses and in reanalyses. Axes are on a log scale. Blue 
indicates identical conclusion between initial analysis and reanalysis. Dots of same 
colors indicate analyses from same study
Table 3 | Some identified challenges (and suggestions) for data sharing and reanalyses
Identified problems Suggested solutions for various stakeholders
Data sharing policies leaves responsibility and burden to 
researchers, to obtain all necessary resources (time, money, 
technical and organizational tools and services, ethical and legal 
compliance, etc)
Patients and clinicians should help to develop awareness of a common ownership of the data, intend-
ed as common responsibility also in providing all necessary resources to make data sharable for effective 
and ethical use 
Researchers should pre-emptively address and seek funding for data sharing 
Funders should allow investigators to use funds towards data sharing 
Academic institutions should reward data sharing activities through promotion and tenure
Getting prepared and preplanning for data sharing is still in 
progress in trials units. There is considerable heterogeneity 
between different procedures to share data and types of data 
that are shared
All stakeholders should adopt some clear and homogeneous rules (eg, guidelines) for best practices in 
data sharing 
Clinical trials groups should develop comprehensive educational outreach about data sharing 
Institutional review boards should systematically address data sharing issues
Data sharing on request leaves researchers exclusive discretion 
on decision about whether to share their own data to other 
research groups, for which objectives, and under which terms 
and conditions
Editors should adopt more binding policies than the current ICJME requirement 
When routine data deposition is not ethically feasible, clinical trials groups should prespecify criteria for 
data sharing by adopting effective and transparent systems to review requests
There could be some difficulties in contacting corresponding 
authors, limiting data sharing on request
Researchersand editors should favor data deposition when it is ethically possible
Some identifying information such as date of birth can be found 
in some databases
Researchers must ensure that databases are deidentified before sharing 
Institutional review board should provide guidance on the requested level of deidentification for each 
individual study. It included seeking consent for sharing IPD from trial participants
Shared databases need to be effectively sharable (eg, complete, 
homogeneous), including meta-data (eg, descriptive labels, 
description of pre-analysis processing tools, methods of analysis)
Clinical trials groups should develop comprehensive educational outreach about data sharing 
Researchers should provide details concerning the detailed labels used in the table and analytical code 
Editors who ask for data and code to be shared should ensure that this material is reviewed
Reproducible research practices are not limited to sharing data, 
materials, and code. Complete reporting of methods and statisti-
cal analyses are also relevant
Clinical trials groups should develop comprehensive educational outreach about data sharing 
Researchers should also share their detailed statistical analysis plan 
Reporting guidelines should emphasize best practices in data sharing about computational reproducibility
RESEARCH
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Medicine—have had no specific policy for data sharing 
in RCTs until recently. Annals of Internal Medicine has 
encouraged (but not demanded) data sharing since 
2007.38 BMC Medicine adopted a similar policy in 2015. 
The BMJ and PLOS Medicine have adopted stronger 
policies, beyond the ICMJE policy, that mandate data 
sharing for RCTs. Our survey of RCTs published in 
these two journals might therefore give a taste of the 
impact and caveats of such full policies. However, care 
should be taken to not generalize these results to other 
journals. First, we had a selected sample of studies. Our 
sample included studies (mostly from Europe) that are 
larger and less likely to be funded by the industry than 
the average published RCT in the medical literature.39 
Several RCTs, especially those published in PLOS 
Medicine, were cluster randomized studies and many 
explored infectious disease or important public health 
issues, characteristics that are not common in RCTs 
overall. Some public funders (or charities) involved in 
their funding have already open access policies, such 
as the Bill and Melinda Gates foundation or the UK 
National Institute for Health Research.
These reasons also explain why we did not compare 
journals. Qualitatively they do not publish the same 
kind of RCTs, and quantitatively The BMJ and PLOS 
Medicine publish few RCTs compared with other leading 
journals, such as the New England Journal of Medicine 
and Lancet. Any comparisons might have been subject 
to confounding. Similarly, we believed that before and 
after studies at The BMJ and PLOS Medicine might have 
been subject to historical bias and confounding factors 
since such policies might have changed the profile 
of submitting authors: researchers with a specific 
interest in open science and reproducibility might 
have been attracted and others might have opted for 
another journal. We think comparative studies will 
be easier to conduct when all journals adopt data 
sharing standards. Even with the current proposed 
ICJME requirements, The BMJ and PLOS Medicine will 
be journals with stronger policies. In addition, The 
BMJ and PLOS Medicine are both major journals with 
many resources, such as in-depth discussion of papers 
in editorial meetings and statistical peer review. Our 
findings concerning reproducibility might not apply 
to smaller journals with more limited resources. We 
cannot generalize this finding to studies that did not 
share their data: authors who are confident in their 
results might more readily agree to share their data 
and this may lead to overestimation of reproducibility. 
In addition, we might have missed a few references 
using the filter “Randomized Controlled Trial[ptyp]”; 
however, this is unlikely to have affected data sharing 
and reproducibility rates.
Finally, in our study the notion of data sharing 
was restricted to a request by a researcher group, 
whereas in theory other types of requestors (patients, 
clinicians, health and academic institutions, etc) may 
also be interested in the data. Moreover, we followed 
the strict procedure presented in the paper and without 
sending any correspondence (eg, rapid response) on 
the journals’ website. In addition, our reanalyses were 
based on primary outcomes, whereas secondary and 
safety outcomes may be more problematic in their 
reproduction. These points need to be explored in 
further studies.
Strengths and weaknesses in relation to other 
studies
In a precedent survey of 160 randomly sampled 
research articles in The BMJ from 2009 to 2015, 
excluding meta-analyses and systematic reviews,40 
the authors found that only 5% shared their datasets. 
Nevertheless, this survey assessed data sharing among 
all studies with original raw data, whereas The BMJ data 
sharing policy specifically applied to clinical trial data. 
When considering clinical trials bound by The BMJ 
data sharing policy (n=21), the percentage shared was 
24% (95% confidence interval 8% to 47%). Our study 
identified higher rates of shared datasets in accordance 
with an increase in the rate of “data shared” for every 
additional year between 2009 and 2015 found in the 
previous survey. It is not known whether it results 
directly from the policy implementation or from a slow 
and positive cultural change of trialists.
Lack of response from authors was also identified as 
a caveat in the previous evaluation, which suggested 
that the wording of The BMJ policy, such as availability 
on “reasonable request,” might be interpreted in 
different ways.40 Previous research across PLOS also 
suggests that data requests by contacting authors 
might be ineffective sometimes.41 Despite writing a 
data sharing agreement in their paper, corresponding 
authors are still free to decline data requests. One 
could question whether sharing data for the purposes 
of our project constitutes a “reasonable request.” One 
might consider that exploring the effectiveness of data 
sharing policies lies outside the purpose for which the 
initial trial was done and for which the participants gave 
consent. A survey found that authors are generally less 
willing to share their data for the purpose of reanalyses 
than, for instance, for individual patient data (IPD) 
meta-analyses.42 Nevertheless, reproducibility checks 
based on independent reanalysis are perfectly aligned 
with the primary objective of clinical trials and indeed 
with patient interests. Conclusions that persist through 
substantial reanalyses are becoming more credible. To 
explain and support the interest of our study, we have 
registered a protocol and have transparently described 
our intentions in our email, but data sharing rates were 
still lower than we expected. Active auditing of data 
sharing policies by journal editors may facilitate the 
implementation of data sharing.
Concerning reproducibility of clinical trials, an 
empirical analysis suggests that only a small number 
of reanalyses of RCTs have been published to date; 
of these, only a minority was conducted by entirely 
independent authors. In a previous empirical 
evaluation of published reanalyses, 35% (13/37) of 
the reanalyses yielded changes in findings that implied 
conclusions different from those of the original article 
as to whether patients should be treated or not or about 
which patients should be treated.43 In our assessment, 
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we found no differences in conclusions pertaining 
to treatment decisions. The difference between the 
previous empirical evaluation and the current one 
is probably due to many factors. It is unlikely that 
published reanalyses in the past would be have been 
published if they had found the same results and had 
reached the same conclusions as the original analysis. 
Therefore, the set of published reanalyses is enriched 
with discrepant results and conclusions. Moreover, 
published reanalyses addressed the same question on 
the same data but using typically different analytical 
methods. Conversely, we used the same analysis 
employed by the original paper. In addition, the good 
computational reproducibility (replication of analyses) 
we found is only one aspect of reproducibility44 
and should not be over-interpreted. For example, in 
psychology, numerous laboratories have volunteered 
to re-run experiments (not solely analyses), with the 
methods used by the original researchers. Overall, 
39 out of 100 studies were considered as successfully 
replicated.45 But attempts to replicate psychological 
studies are often easier to implement than attempts to 
replicate RCTs, which are often costly and difficult to 
run. This is especially true for large RCTs.
Meaning of the study: possible explanations and 
implications for clinicians and policy makers
The ICJME’s requirements adopted in 2017 mandate 
that a data sharing plan will have to be included in 
each paper (and prespecified in study registration).8 
Because data sharing among two journals with 
stronger requirements was not optimal, our results 
suggest that this not likely to be sufficient to achieve 
high rates of data sharing. One can imagine that 
individual authors will agree to write such a statement 
in line with the promise of publication, but the time 
and costs involved into such data preparation might 
lead authors to be reluctant to answer data sharing 
requests. Interestingly the ICJME also mandates that 
clinical trials that begin enrolling participants on or 
after 1 January 2019 must include a data sharing plan 
in the trial’s registration. An a priori data sharing plan 
might push more authors to pre-emptively deal with 
and find funding for sharing, but its eventual impact 
on sharing is unknown. Funders are well positioned 
to facilitate data sharing. Some, such as the Wellcome 
Trust, already allow investigators to use funds towards 
the charges for open access, which is typically a small 
fraction of awarded funding. Funders could extend 
their funding policy and also allow investigators to use 
a similar small fraction of funding towards enabling 
data sharing. In addition, patients can help promote a 
culture of data sharing for clinical trials.5
In addition, reproducible research does not solely 
imply sharing data but also reporting all steps of the 
statistical analysis. This is one core principle of the 
CONSORT statement “Describe statistical methods 
with enough detail to enable a knowledgeable reader 
with access to the original data to verify the reported 
results.”46 It is none the less sometimes difficult to 
provide such detailed information in a restricted 
number of lines (ie, a paper). We suggest that details of 
the statistical analysis plan have to be provided as well 
as the detailed labels used in the table, and efficient 
analytical code sharing is also essential.47
We suggest that if journals ask for data and code 
to be shared, they should ensure that this material is 
also reviewed by editorial staff (with or without peer 
reviewers) or at a minimum checked for completeness 
and basic usability.47 This could also be positively 
translated in specific incentives for the paper; for 
example, many psychology journals use badges15 
as signs of good research practices (including data 
sharing) adopted by papers. And, beyond incentivizing 
authors, journals adopting such practices could also be 
incentivized by a gain in reputation and credibility.
Though ensuring patient privacy and lack of 
explicit consent for sharing are often cited as major 
barriers to sharing RCT data (and generally accepted 
as valid exemptions),48 none of the investigators we 
approached mentioned this reason. This could suggest 
that technical constraints, lack of incentives and 
dedicated funding, and a general diffidence towards 
reanalyses might be more germane obstacles to be 
addressed.
Finally, data sharing practices differed from one team 
to another. There is thus a need for standardization and 
for drafting specific guidelines for best practices in data 
sharing. In the United Kingdom, the Medical Research 
Council Hubs for Trials Methodology Research has 
proposed a guidance to facilitate the sharing of IPD for 
publicly funded clinical trials.49-51 Other groups might 
consider adopting similar guidelines.
Unanswered questions and future research
We recommend some prospective monitoring of data 
sharing practices to ensure that the new requirements 
of the ICJME are effective and useful. To this end, it 
should also be kept in mind that data availability is 
a surrogate of the expected benefit of having open 
data. Proving that data sharing rates impacts reuse52 
of the data is a further step. Proving that this reuse 
might translate into discovery that can change care 
without generating false positive findings (eg, in series 
of unreliable a posteriori subgroup analyses) is even 
more challenging.
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